(Q46245713)

20 December 2017

title

The new immunosuppressive agent FK778 attenuates neointima formation in an experimental venous bypass graft model (English)

1 reference

20 December 2017

author name string

Rick de Graaf

1

1 reference

20 December 2017

Geoffrey Kloppenburg

2

1 reference

20 December 2017

Andrei Tintu

3

1 reference

20 December 2017

Ellen Rouwet

4

1 reference

20 December 2017

Peter Kitslaar

5

1 reference

20 December 2017

Johannes van Hooff

6

1 reference

20 December 2017

Cathrien Bruggeman

7

1 reference

20 December 2017

Frank Stassen

8

1 reference

20 December 2017

publication date

5 November 2008

1 reference

20 December 2017

published in

Vascular Pharmacology

1 reference

20 December 2017

volume

50

1 reference

20 December 2017

issue

3-4

1 reference

20 December 2017

page(s)

83-88

1 reference

20 December 2017

Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2008.10.005

Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial. Post CABG Trial Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2008.10.005

A Platelet-Inhibitor-Drug Trial in Coronary-Artery Bypass Operations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2008.10.005

Genetic interventions for vein bypass graft disease: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2008.10.005

Down-regulation of TGF-beta and VCAM-1 is associated with successful treatment of chronic rejection in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2008.10.005

The antiproliferative effect of malononitrilamides (MNAs) on vascular smooth muscle cells is antagonized by exogenous uridine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2008.10.005

Prevention and inhibition but not reversion of chronic allograft vasculopathy by FK778.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2008.10.005

FK778 attenuates lymphocyte-endothelium interaction after cardiac transplantation: in vivo and in vitro studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2008.10.005

Inhibition of human cytomegalovirus signaling and replication by the immunosuppressant FK778.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2008.10.005

Oral everolimus inhibits in-stent neointimal growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2008.10.005

Treatment of saphenous vein graft lesions with drug-eluting stents: immediate and midterm outcome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2008.10.005

Oral rapamycin to prevent human coronary stent restenosis: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2008.10.005

Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2008.10.005

2005 Dr. Gary J. Becker Young Investigator Award: periprocedural oral administration of the leflunomide analogue FK778 inhibits neointima formation in a double-injury rat model of restenosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2008.10.005

A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2008.10.005

Identification and characterization of potential new therapeutic targets in inflammatory and autoimmune diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2008.10.005

Inhibition of smooth muscle cell proliferation in vitro by leflunomide, a new immunosuppressant, is antagonized by uridine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2008.10.005

Chronic ACE Inhibition Reduces Intimal Hyperplasia in Experimental Vein Grafts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2008.10.005

Production and inhibition of the gelatinolytic matrix metalloproteinases in a human model of vein graft stenosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2008.10.005

Leflunomide analogue FK778 is vasculoprotective independent of its immunosuppressive effect: potential applications for restenosis and chronic rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2008.10.005

Inhibition of restenosis development after mechanical injury: a new field of application for malononitrilamides?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2008.10.005

Systematic review of randomized controlled trials of aspirin and oral anticoagulants in the prevention of graft occlusion and ischemic events after infrainguinal bypass surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2008.10.005

Dose-dependent inhibition of myointimal hyperplasia by orally administered rapamycin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2008.10.005

The effects of FK778 in combination with tacrolimus and steroids: a phase II multicenter study in renal transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2008.10.005

Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2008.10.005

Mechanistic study of malononitrileamide FK778 in cardiac transplantation and CMV infection in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2008.10.005

10.1016/J.VPH.2008.10.005

7 January 2021

Identifiers

DOI

1 reference

20 December 2017

1 reference

20 December 2017